Comparison of Diaphragmatic Breathing and Muscle Relaxation for Rumination

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT01576302
Collaborator
(none)
13
1
2
32
0.4

Study Details

Study Description

Brief Summary

Rumination is an upper gastrointestinal (GI) disorder characterized by the frequent regurgitation of recently ingested food. Very little is understood about the nature and treatment of this disorder. The act of regurgitation in rumination involves the opening of the upper esophageal sphincter and the muscular contraction of the abdomins rectus. Behavioral treatment of these symptoms is the clinical intervention of choice; however, only uncontrolled case documentation exists to support its effectiveness. However, an effective behavioral mechanism may be relaxation of the muscles. From a behavioral standpoint, muscular relaxation is incompatible with the necessary muscular contraction for rumination.

To date, single case documentation and few designed single case studies have examined the clinical effectiveness of behavioral interventions for GI rumination. In the current study, the investigators seek to examine the effectiveness of two behavioral relaxation interventions for GI rumination through a treatment as usual paradigm (proposed N = 20). Our primary goals are to examine the clinical effectiveness of these interventions in symptom reduction at 1- and 3-month follow-up.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Diaphragmatic breathing
  • Behavioral: Muscle relaxation
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
13 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Diaphragmatic Breathing and Progressive Muscle Relaxation: Behavioral Interventions for Gastrointestinal Rumination
Study Start Date :
Apr 1, 2012
Actual Primary Completion Date :
Dec 1, 2014
Actual Study Completion Date :
Dec 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Diaphragmatic breathing

Training in diaphragmatic breathing as response incompatible with rumination.

Behavioral: Diaphragmatic breathing
Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).

Behavioral: Muscle relaxation
Progressive passive muscle relaxation
Other Names:
  • Relaxation training
  • Progressive Muscle Relaxation
  • Active Comparator: Muscle relaxation

    Patients in this arm of study will be taught muscle relaxation as intervention for rumination, instructed in habit-reversal paradigm to use after eating food or if urge to ruminate

    Behavioral: Muscle relaxation
    Progressive passive muscle relaxation
    Other Names:
  • Relaxation training
  • Progressive Muscle Relaxation
  • Outcome Measures

    Primary Outcome Measures

    1. Rumination Frequency assessed using Rome III Criteria [1 month after intervention]

      Study participants will be treated with diaphragmatic breathing in one arm and muscle relaxation in the other arm. Outcome measure is: Rome III Study Questions Q8: In the last week, how often did food come back up into your mouth? Q10: When food came back up into your mouth, did it usually stay in your mouth for a while before you swallowed it or spit it out?

    2. Rumination frequency assessed using Rome III Criteria [3 months after intervention]

      Study participants will be treated with diaphragmatic breathing in one arm and muscle relaxation in the other arm. Outcome measure is: Rome III Study Questions Q8: In the last week, how often did food come back up into your mouth? Q10: When food came back up into your mouth, did it usually stay in your mouth for a while before you swallowed it or spit it out?

    Secondary Outcome Measures

    1. Heath Care Utilization [1 month after intervention]

      How many healthcare visits would you estimate were related to rumination since you started the intervention?

    2. Short Health Anxiety Inventory (SHAI) [1 month post intervention]

      Measure of degree to which intervention has impacted health concerns/anxiety. The SHAI is a validated measure

    3. Sheehan Disability Scale (SDS) [1 month after intervention]

      This is a measure of the impact of symptoms on Work, Family, and Social life. Uses a 10 point scale --with categories of mild,moderate severe

    4. Treatment adherence [1 month after intervention]

      Following question will be posed: Did you engage in the intervention as you were instructed at your training session? The responses will be categorized for themes.

    5. Heath Care Utilization [3 month after intervention]

      How many healthcare visits would you estimate were related to rumination since you started the intervention?

    6. Short Health Anxiety Inventory (SHAI) [3 months post intervention]

      Measure of degree to which intervention has impacted health concerns/anxiety. The SHAI is a validated measure

    7. Sheehan Disability Scale (SDS) [3 months after intervention]

      This is a measure of the impact of symptoms on Work, Family, and Social life. Uses a 10 point scale --with categories of mild,moderate severe

    8. Treatment adherence [3 months after intervention]

      Following question will be posed: Did you engage in the intervention as you were instructed at your training session? The responses will be categorized for themes.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. At least 18 years of age.

    2. Diagnosis of rumination by RomeIII criteria

    Exclusion Criteria:
    1. Active alcohol or substance abuse

    2. Presence of a depressive disorder as measured by PHQ-9 score of 10 or above

    3. Presence of clinical significant anxiety disorder as measured by GAD-7 score of 10 or above.

    4. Severe levels of health focused anxiety as measured by SHAI score of 26 or above.

    5. Any medical, neurological, or psychiatric condition that would impair the ability to consent and carry out all study procedures.

    6. Any active psychosis or suicidality.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

    Sponsors and Collaborators

    • Mayo Clinic

    Investigators

    • Principal Investigator: Richard Seime, PhD, LP, Mayo Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Richard J. Seime, PHD, Mayo Clinic
    ClinicalTrials.gov Identifier:
    NCT01576302
    Other Study ID Numbers:
    • 11-008528
    First Posted:
    Apr 12, 2012
    Last Update Posted:
    Dec 10, 2014
    Last Verified:
    Dec 1, 2014
    Keywords provided by Richard J. Seime, PHD, Mayo Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 10, 2014